SAN
DIEGO, June 26, 2023
/PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a
clinical-stage cell and gene therapy company advancing a new class
of treatments for patients with cancer and rare diseases, today
announced it is set to join both the broad-market Russell
3000® and small-cap Russell 2000® Indexes at
the conclusion of the 2023 Russell indexes annual reconstitution,
effective after the U.S. market opens today, according to a
preliminary list of additions posted following the close of the
U.S. markets on May 19, 2023.
"We are pleased to be included in the Russell U.S. Indexes,
which stands as a testament to the significant progress we have
made across our cell and gene therapy portfolios," said
Mark Gergen, Chief Executive Officer of Poseida. "With this
inclusion, we believe that the increased visibility amongst the
global investment community will help us continue to build
awareness among investors as we work to redefine cell and gene
therapies for patients with high unmet medical need."
The annual Russell indexes reconstitution captures the 4,000
largest U.S. stocks as of April 28,
2023, ranking them by total market capitalization.
Membership in the U.S. all-cap Russell 3000® Index,
which remains in place for one year, means automatic inclusion in
the small-cap Russell 2000® Index or the large-cap
Russell 1000® Index as well as the appropriate growth
and value style indexes. FTSE Russell determines membership for its
Russell indexes primarily by objective, market-capitalization
rankings and style attributes.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $12.1 trillion in assets are benchmarked
against Russell's U.S. indexes. Russell indexes are part of
FTSE Russell, a leading global index provider.
For more information on the Russell 3000® Index
and the Russell indexes reconstitution, go to the "Russell
Reconstitution" section on the FTSE Russell website.
About Poseida Therapeutics, Inc.
Poseida Therapeutics
is a clinical-stage biopharmaceutical company advancing
differentiated cell and gene therapies with the capacity to cure
certain cancers and rare diseases. The Company's pipeline includes
allogeneic CAR-T cell therapy product candidates for both solid and
liquid tumors as well as in vivo gene therapy product candidates
that address patient populations with high unmet medical need. The
Company's approach to cell and gene therapies is based on its
proprietary genetic editing platforms, including its
non-viral piggyBac® DNA Delivery System,
Cas-CLOVER™ Site-Specific Gene Editing System and
nanoparticle and hybrid gene delivery technologies. The Company has
formed a global strategic collaboration with Roche to unlock
the promise of cell therapies for patients. Learn more at
www.poseida.com and connect with us on Twitter and
LinkedIn.
About FTSE Russell
FTSE Russell is a global index leader that provides innovative
benchmarking, analytics and data solutions for investors worldwide.
FTSE Russell calculates thousands of indexes that measure and
benchmark markets and asset classes in more than 70 countries,
covering 98% of the investable market globally.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. Approximately
$20.1 trillion is currently
benchmarked to FTSE Russell indexes. For over 30 years, leading
asset owners, asset managers, ETF providers and investment banks
have chosen FTSE Russell indexes to benchmark their investment
performance and create ETFs, structured products and index-based
derivatives.
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants.
FTSE Russell is focused on applying the highest industry standards
in index design and governance and embraces the IOSCO Principles.
FTSE Russell is also focused on index innovation and customer
partnerships as it seeks to enhance the breadth, depth and reach of
its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit www.ftserussell.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements include statements
regarding, among other things, expected plans with respect to
clinical trials, including timing of regulatory submissions and
approvals and clinical data updates; potential fees, milestones and
other payments that the Company may receive pursuant to its
collaboration agreement; anticipated timelines and milestones with
respect to the Company's development programs and manufacturing
activities and capabilities; the potential capabilities and
benefits of the Company's technology platforms and product
candidates; and the Company's plans and strategy with respect to
developing its technologies and product candidates. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. These forward-looking statements are
based upon the Company's current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results could differ materially from those
anticipated in such forward-looking statements as a result of
various risks and uncertainties, which include, without limitation,
the Company's reliance on third parties for various aspects of its
business; risks and uncertainties associated with development and
regulatory approval of novel product candidates in the
biopharmaceutical industry; the Company's ability to retain key
scientific or management personnel; the fact that the Company will
have limited control over the efforts and resources that its
strategic partner devotes to advancing development programs under
its collaboration agreement and the Company may not receive the
potential fees and payments under the collaboration agreement and
the ability of its strategic partner to early terminate the
collaboration, such that the Company may not fully realize the
benefits of such collaboration; and the other risks described in
the Company's filings with the Securities and Exchange Commission.
All forward-looking statements contained in this press release
speak only as of the date on which they were made. The Company
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made, except as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-to-join-russell-3000-and-russell-2000-indexes-301861027.html
SOURCE Poseida Therapeutics, Inc.